"versionIdentifier","rationale","id","instanceType","uuid:ID"
"2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion_1","StudyVersion","8a66ab75-7a15-4237-a8b1-0165d026538f"
